Search Result

Results for "

thalassemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) COX (2) Ferroportin (2) Ferroptosis (2) HCV (2) Histone Methyltransferase (2) Phosphodiesterase (PDE) (1) Ser/Thr Protease (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (7) Endocrinology (2) Infection (2) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131060

CN128 hydrochloride CN328	Others	Others
CN128 hydrochloride (CN328) is an orally active and selective iron chelator. CN128 is used for the research of β-thalassemia .

HY-112220

VIT-2763 1 Publications Verification	Ferroportin	Metabolic Disease
VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia .

HY-108260

Deferitrin GT-56-252	Others	Cardiovascular Disease
Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-114643

(Rac)-Tovinontrine (Rac)-IMR-687	Phosphodiesterase (PDE)	Cardiovascular Disease
(Rac)-Tovinontrine ((Rac)-IMR-687) is a phosphodiesterase 9 (PDE9) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. (Rac)-Tovinontrine is promising for research of thalassemia .

HY-163819

WIZ degrader 3	Others	Cardiovascular Disease
WIZ degrader 3 (Compound 29) is a degrader for widely interspaced zinc finger motifs (WIZ), with an AC₅₀ of 6.4 nM. WIZ degrader 3 induces the expression of fetal hemoglobin (HbF), with an EC₅₀ of 45 nM. WIZ degrader 3 can be used for the research of blood disorders, such as sickle cell disease and β- thalassemia .

HY-163820

WIZ degrader 4	Others	Others
WIZ degrader 4 (Example 1) is a WIZ degrader with an AC₅₀ value of 160 nM. WIZ degrader 4 can be used to investigate sickle cell disease (SCD) and thalassemia .

HY-163824

WIZ degrader 7	Others	Others
WIZ degrader 7 (Example 16) is a WIZ degrader with an IC₅₀ value of < 0.01 μM. WIZ degrader 7 can be used to investigate sickle cell disease (SCD) and thalassemia .

HY-160078

Deferiprone O-β-D-glucuronide	Others	Metabolic Disease
Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide shows the capability of reducing the iron burden in patients with β-thalassemia .

HY-130136

TMPRSS6-IN-1	Ser/Thr Protease	Others
TMPRSS6-IN-1 (compound 8) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .

HY-139400A

Pociredir hydrochloride FTX-6058 hydrochloride	Histone Methyltransferase	Cardiovascular Disease
Pociredir (FTX-6058) hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir hydrochloride can induce HbF protein expression in cell and murine models. Pociredir hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .

HY-139400

Pociredir FTX-6058	Histone Methyltransferase	Cardiovascular Disease
Pociredir (FTX-6058) is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir can induce HbF protein expression in cell and murine models. Pociredir can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .

HY-16912

SP-420	Others	Others
SP-420 is a tridentate iron chelator belonging to the class of iron chelators, with oral activity. It is a derivative of desferrithiocin but has higher iron clearance efficiency and minimized renal toxicity compared to desferrithiocin, with an ICE (Iron Clearance Efficiency) value of 26.7. SP-420 can be used in research related to β-thalassemia .

HY-B0568

Deferiprone 35+ Cited Publications	Ferroptosis HCV Apoptosis COX	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .

HY-B0568R

Deferiprone (Standard)	Ferroptosis HCV Apoptosis COX	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
Deferiprone (Standard) is the analytical standard of Deferiprone. This product is intended for research and analytical applications. Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library	2,930 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 2,930 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

2,930 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 2,930 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Cat. No.	Product Name	Target	Research Area

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.